The Hastings Center: Should we enroll our child in a COVID-19 vaccine trial?
UC professor and Cincinnati Children's ethicist tackles a weighty topic as the pandemic continues
Elizabeth Lanphier, PhD, an assistant professor in the UC Department of Pediatrics, is also a clinical ethics at Cincinnati Children’s Hospital Medical Center. As part of an opinion piece Lanphier discusses her own family’s choices in deciding whether to enroll a child in Pfizer’s clinical trial which is recruiting 5-to-11 year olds.
Elizabeth Lanphier, PhD.
“As a clinical ethicist I am engaged in weighing risks and benefits of medical decisions,” writes Lanphier. “Yet when it comes to doing this for my child and family, it’s complicated. Risks and benefits of Covid-19 vaccine trials are multi-faced, sometimes uncertain, and difficult to quantify.
Let’s start with what is clear. In my family, the benefits of Covid-19 vaccination far outweigh the known risks. My spouse and I were vaccinated when eligible.”
Read the full opinion piece penned by Elizabeth Lanphier, PhD, online.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.